

## **EXEMPLARY PK STUDY RESULTS MOVE RP11 PROGRAM CLOSER TO FIRST IN HUMAN TRIALS**

*PYC has completed Pharmacokinetic (PK) studies in Non-Human Primates (NHP) in the Company's most advanced program for the treatment of a blinding eye disease called Retinitis Pigmentosa type 11 (RP11)*

*The results of these PK studies support both the progression of the Company's investigational drug candidate for RP11 into 'first in human' evaluation and the utility of PYC's next generation RNA platform technology for the treatment of retinal disease*

*The results confirm three critical drug-like properties of PYC's investigational drug candidate:*

- *Distribution of the drug to the target cells in the eye (necessary to have a meaningful effect)*
- *Extended residence time of the drug in target cells (supporting a long interval between doses as preferred by patients); and*
- *Minimal off-target distribution of the drug (reducing the likelihood of unintended adverse treatment events)*

**PERTH, Australia and SAN DIEGO, California – 10 May, 2022** – PYC Therapeutics (ASX:PYC) is a biotechnology company combining two complementary platform technologies:


- RNA based drug design; and
- a proprietary drug delivery technology.

Together they are being developed to create a new generation of RNA therapeutics to change the lives of patients with genetic diseases.

With the successful completion of pharmacokinetic (PK) studies in Non-Human Primates (NHPs), the Company has now established that this new generation of RNA therapeutic has an attractive PK profile for the treatment of blinding eye diseases of the retina.

The results were generated in PYC's most advanced investigational drug candidate currently being developed to treat patients with an inherited blinding eye disease called Retinitis Pigmentosa type 11 (RP11). This program is the first in PYC's pipeline of next generation RNA therapies progressing towards clinical development. There are no approved therapies for RP11 nor are there any investigational entities specifically targeting RP11 currently in clinical trials.

**Figure 1.** Half-life profile of PYC's investigational drug candidate for RP11 (VP-001) in Non-Human Primate retina demonstrating drug presence in the neural retina ('retina') and Retinal Pigment Epithelium/choroid (RPE/choroid) (the target cellular layers affected in RP11) 112 days after a single intravitreal administration.



PYC is on track to submit an Investigational New Drug application (IND) in support of its RP11 drug candidate with the US Food and Drug Administration in the second half of this year. The Good Laboratory Practice toxicology studies required to support this IND have already commenced. A successful IND will be followed by commencement of 'first in human' studies – marking the transition of PYC to a clinical stage Company with the first product borne out of its next generation platform for the creation of novel RNA therapeutics.

This announcement was approved for release by the Board of PYC Therapeutics.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilise the Company's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodegenerative and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are located in Australia and its translational, clinical, regulatory and business development operations are located in the United States. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

### Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and*

*other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

## **CONTACTS:**

### **INVESTORS**

info@pyctx.com

### **MEDIA**

Michelle Di Lello

Michelle.DiLello@pyctx.com